Financial intelligence for Asia's healthcare markets
Remember me:

News articles    

Kuala Lumpur-based private investment firm RHL Ventures has invested in healthcare SaaS platform HealthMetrics’ follow on round. The size of the investment has not been disclosed.
Ophtecs, a manufacturer of contact lens solutions headquartered in Kobe City, Japan, has acquired a 100% stake in Dutch contact lens manufacturer Microlens Contactlens Technolgy. The purchase price is undisclosed.
Germany’s Indivumed has launched the "Cancer Library Initiative", an operation to further accelerate precision diagnostics and personalised treatment for cancer patients, in collaboration with A*STAR's Institute of Molecular and Cell Biology (IMCB) in Singapore.
Fujifilm has announced plans to invest ¥10 billion (US$90 million) in order to expand its bio contract development and manufacturing organisation (CDMO) business. This investment will include the expansion of existing production facilities at its North Carolina location to support the growing needs of its customer portfolio.
OrigiMed has formally announced the completion of its Series B financing. This round of financing is led by Grand Flight Investment. The pre-A financing investor Wedo Capital continued to invest.
Ascentage Pharma and The University of Texas MD Anderson Cancer Center have announced a five-year strategic collaboration agreement to advance the development of five potential new cancer therapies.
Antengene, a clinical stage therapeutics company focused on oncology, has completed US$120 million Series B funding. It was jointly led by Boyu Capital and FountainVest, with participation from Celgene Corporation, WuXi AppTec, and Taikang.
HJB and MabSpace Biosciences have entered into a definitive merger agreement to create Transcenta Holding, a class biotherapeutics company with fully integrated capabilities in research, development, regulatory and manufacturing of biologics.
WuXi Biologics, a global open-access biologics technology platform company that offers end-to-end solutions for biologics discovery, development and manufacturing and AC Immune, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, have announced an exclusive strategic collaboration that covers biologics discovery, development and manufacturing.
Medibank and ahm health insurance premiums will increase by an average of 3.3% from 1 April 2019 – its lowest average premium increase in 18 years.

Subscribe to our news RSS feed Get the RSS for HealthInvestor Asia




Hong Kong-listed Life Healthcare Group has cancelled plans to raise up to HK$128.5 million (US$16.4 million) in a share placement of up to 20% of its share capital. CNI Securities Group was the agent.



HealthInvestor Asia twitter feed


HealthInvestor UK